DrugPatentWatch Database Preview
FABIOR Drug Profile
or, see our see our flat-rate plans
Which patents cover Fabior, and what generic alternatives are available?
This drug has nineteen patent family members in thirteen countries.
The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
Summary for FABIOR
| International Patents: | 19 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 91 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,251 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | FABIOR at DailyMed |
Synonyms for FABIOR
| 118292-40-3 |
| 15146-EP2275420A1 |
| 15146-EP2295055A2 |
| 15146-EP2295416A2 |
| 15146-EP2298748A2 |
| 15146-EP2298764A1 |
| 15146-EP2298765A1 |
| 15146-EP2298768A1 |
| 15146-EP2305642A2 |
| 15146-EP2308861A1 |
| 15146-EP2311453A1 |
| 15146-EP2311808A1 |
| 15146-EP2311829A1 |
| 15146-EP2314590A1 |
| 15146-EP2316832A1 |
| 15146-EP2316833A1 |
| 292T403 |
| 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester |
| 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester |
| 4CA-1215 |
| 6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester |
| 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester |
| 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester |
| 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester |
| 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester |
| 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester |
| 81BDR9Y8PS |
| AB0012671 |
| AB01274801_02 |
| AB01274801-01 |
| AB2000146 |
| ABP000994 |
| AC-755 |
| AC1L1K88 |
| Acnitaz |
| ACT06773 |
| AGN 190168 |
| AGN-190168 |
| AJ-26850 |
| AK-73028 |
| AKOS015902872 |
| AN-15540 |
| ANW-45265 |
| Avage |
| Avage (TN) |
| AX8041205 |
| BC201578 |
| BCP0726000163 |
| BDBM50265951 |
| BIDD:GT0293 |
| BR-73028 |
| BS-1012 |
| C-23771 |
| C12531 |
| C21H21NO2S |
| CAS-118292-40-3 |
| CC-34651 |
| CHEBI:32184 |
| CHEMBL1657 |
| CJ-24315 |
| CS-1029 |
| CTK8B4490 |
| D01132 |
| D0BM5G |
| DB00799 |
| DR001785 |
| DSSTox_CID_26691 |
| DSSTox_GSID_46691 |
| DSSTox_RID_81825 |
| DTXSID5046691 |
| EBD38650 |
| Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate |
| Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester |
| ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate |
| ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate |
| ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate |
| Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate |
| ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate |
| ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate |
| Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate |
| ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate |
| Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate |
| ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate |
| Fabior (TN) |
| FT-0652578 |
| GTPL6952 |
| HE299896 |
| HMS3655K05 |
| HY-15388 |
| I14-1992 |
| KB-80817 |
| LS-130838 |
| MFCD00867628 |
| MLS003915630 |
| MolPort-005-932-693 |
| NCGC00167525-01 |
| NCGC00167525-02 |
| NCGC00167525-03 |
| OGQICQVSFDPSEI-UHFFFAOYSA-N |
| PubChem24431 |
| Q-102516 |
| RTR-034197 |
| S-7551 |
| s1569 |
| SC-19506 |
| SCHEMBL3134 |
| SMR002096194 |
| SR-01000931253 |
| SR-01000931253-2 |
| ST2419369 |
| Suretin |
| tazarotene |
| Tazarotene (Avage) |
| Tazarotene (JAN/USAN/INN) |
| Tazarotene [USAN:INN:BAN] |
| Tazarotene [USAN:INN] |
| tazaroteno |
| tazarotenum |
| Tazorac |
| Tazorac (TN) |
| Tazorac, Avage, Zora, Tazarotene |
| Tazorac;Avage;Zora;Avage |
| Tazoral |
| Tox21 112522 |
| Tox21_112522 |
| Tox21_112522_1 |
| TR-034197 |
| UNII-81BDR9Y8PS |
| ZINC1542199 |
| Zora |
| Zorac |
| Zorac (TN) |
| Zorac|||Tazorac |
US Patents and Regulatory Information for FABIOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | FABIOR | tazarotene | AEROSOL, FOAM;TOPICAL | 202428-001 | May 11, 2012 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
International Patents for FABIOR
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201171079 | ➤ Try a Free Trial |
| European Patent Office | 2400951 | ➤ Try a Free Trial |
| Mexico | 2011008912 | ➤ Try a Free Trial |
| Israel | 214520 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for FABIOR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /1998 | Austria | ➤ Try a Free Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203 |
| C/GB98/002 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 |
| C0008 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
